Drugs / 18F-fluoromisonidazole
18F-fluoromisonidazole
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04861077 | Jun 2026 → Aug 2028 expected | triple-negative breast carcinoma | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 0 | NCT05996432 | May 2023 → Nov 2026 expected | head and neck squamous cell carcinoma, metastatic malignant neoplasm in the brain | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
| Phase 0 | NCT01967927 | Dec 2013 → Aug 2021 | head and neck squamous cell carcinoma | University of Arkansas | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 13 trials | ||||||
| Phase 1 | NCT04332588 | Mar 2022 → Aug 2027 expected | HER2 positive breast carcinoma | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 1 | NCT03730077 | Feb 2019 → Feb 2021 | soft tissue sarcoma | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 1 | NCT03573986 | Apr 2018 → Jan 2020 | glioblastoma | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT02695628 | Sep 2016 → Apr 2018 | cirrhosis of liver, hepatocellular carcinoma | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT02471313 | Jun 2015 → Mar 2018 | hepatocellular carcinoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2 | NCT02061007 | Oct 2014 → Feb 2016 | melanoma, skin cancer | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01868906 | Jun 2013 → Sep 2017 | malignant glioma | Bernardino Clavo, MD, PhD | Terminated | No outcome recorded |
| Phase 2 | NCT01898065 | Jun 2012 → Nov 2014 | prostate adenocarcinoma | Institut Cancerologie de l'Ouest | Completed | No outcome recorded |
| Phase 2 | NCT01507428 | Feb 2012 → Aug 2020 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase not applicable2 trials | ||||||
| — | NCT02016872 | Dec 2013 → Jul 2024 | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00038038 | Jan 1994 → Jun 2003 | head and neck neoplasm, metastatic neoplasm, squamous cell carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-fluoromisonidazole | “18F-fluoromisonidazole (FMISO) positron emission tomography (PET) is a non-invasive, quantitative imaging technique used to evaluate the presence and spatial distribution of...” PMID 27822900 ↗ Nov 2016 |
| Known as | 18F-FMISO | “experimental drug, 18F-fluoromisonidazole (18F-FMISO), visualized with PET scanning.” NCT00038038 ↗ |
| Known as | 18F-MISO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01967927 ↗ |
| Known as | FMISO | “18F-fluoromisonidazole (FMISO) positron emission tomography (PET) is a non-invasive, quantitative imaging technique used to evaluate the presence and spatial distribution of...” PMID 27822900 ↗ Nov 20161“Fludeoxyglucose (18F) fluoromisonidazole (FMISO), in patients diagnosed with triple negative breast cancer” NCT04861077 ↗ |
| Modality | Diagnostic / imaging agent | “using 18F-fluoromisonidazole as an imaging agent” NCT00038038 ↗ |
| Route | Intravenous | “IV line placed for radiotracer injection” NCT02016872 ↗ |